Emergency use approval has been granted in India for the anti-covid therapeutic application of the drug 2-Deoxy-D-Glucose (2-DG) developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a lab of the DRDO, in collaboration with Dr. Reddy’s Laboratories.
2DG is an oral antiviral drug that can be administered only upon prescription to hospitalized Moderate to Severe Covid-19 patients as adjunct (add-on) therapy along with the existing standard of care.
Commercial launch and supply of 2-DG to major Government and Private hospitals is expected to commence in mid-June. Price is being determined with a view to making it accessible and affordable to as many patients as possible and will be announced soon.
2DG has not yet been launched into the market. The price per sachet has not yet been announced. Please beware of agents selling spurious or illegal products in the name of 2DG. For more information, one can write an email to 2DG@drreddys.com.